Rosenblum D[au] - Search Results

Year	Number of Results
1950	2
1956	2
1957	1
1959	2
1963	2
1964	3
1965	1
1966	1
1968	1
1970	1
1972	1
1973	2
1975	1
1978	1
1980	2
1981	1
1983	1
1988	2
1991	1
1993	3
1994	1
1995	1
1998	5
1999	2
2001	2
2003	2
2004	1
2006	2
2007	2
2009	3
2010	3
2011	3
2012	4
2013	9
2014	6
2015	2
2016	6
2017	3
2018	5
2019	4
2020	7
2021	2

1

CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.

Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, Schubert MS, Friedmann-Morvinski D, Cohen ZR, Behlke MA, Lieberman J, Peer D. Rosenblum D, et al. Sci Adv. 2020 Nov 18;6(47):eabc9450. doi: 10.1126/sciadv.abc9450. Print 2020 Nov. Sci Adv. 2020. PMID: 33208369 Free PMC article.

2

Progress and challenges towards targeted delivery of cancer therapeutics.

Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Rosenblum D, et al. Nat Commun. 2018 Apr 12;9(1):1410. doi: 10.1038/s41467-018-03705-y. Nat Commun. 2018. PMID: 29650952 Free PMC article. Review.

3

A modular platform for targeted RNAi therapeutics.

Kedmi R, Veiga N, Ramishetti S, Goldsmith M, Rosenblum D, Dammes N, Hazan-Halevy I, Nahary L, Leviatan-Ben-Arye S, Harlev M, Behlke M, Benhar I, Lieberman J, Peer D. Kedmi R, et al. Among authors: rosenblum d. Nat Nanotechnol. 2018 Mar;13(3):214-219. doi: 10.1038/s41565-017-0043-5. Epub 2018 Jan 29. Nat Nanotechnol. 2018. PMID: 29379205

4

Progress and challenges towards CRISPR/Cas clinical translation.

Rosenblum D, Gutkin A, Dammes N, Peer D. Rosenblum D, et al. Adv Drug Deliv Rev. 2020;154-155:176-186. doi: 10.1016/j.addr.2020.07.004. Epub 2020 Jul 10. Adv Drug Deliv Rev. 2020. PMID: 32659256 Review.

5

The Technological Impact of COVID-19 on the Future of Education and Health Care Delivery.

Shah S, Diwan S, Kohan L, Rosenblum D, Gharibo C, Soin A, Sulindro A, Nguyen Q, Provenzano DA. Shah S, et al. Among authors: rosenblum d. Pain Physician. 2020 Aug;23(4S):S367-S380. Pain Physician. 2020. PMID: 32942794 Free article.

6

Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes.

Veiga N, Goldsmith M, Granot Y, Rosenblum D, Dammes N, Kedmi R, Ramishetti S, Peer D. Veiga N, et al. Among authors: rosenblum d. Nat Commun. 2018 Oct 29;9(1):4493. doi: 10.1038/s41467-018-06936-1. Nat Commun. 2018. PMID: 30374059 Free PMC article.

7

Fentanyl: the many challenges ahead.

Mars SG, Rosenblum D, Ciccarone D. Mars SG, et al. Among authors: rosenblum d. Addiction. 2019 May;114(5):785-786. doi: 10.1111/add.14587. Epub 2019 Mar 15. Addiction. 2019. PMID: 30873700 No abstract available.

8

Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target.

Veiga N, Goldsmith M, Diesendruck Y, Ramishetti S, Rosenblum D, Elinav E, Behlke MA, Benhar I, Peer D. Veiga N, et al. Among authors: rosenblum d. J Control Release. 2019 Nov 10;313:33-41. doi: 10.1016/j.jconrel.2019.10.001. Epub 2019 Oct 18. J Control Release. 2019. PMID: 31634546

9

Systemic Modulation of Lymphocyte Subsets Using siRNAs Delivered via Targeted Lipid Nanoparticles.

Hazan-Halevy I, Rosenblum D, Ramishetti S, Peer D. Hazan-Halevy I, et al. Among authors: rosenblum d. Methods Mol Biol. 2019;1974:151-159. doi: 10.1007/978-1-4939-9220-1_11. Methods Mol Biol. 2019. PMID: 31099001

10

Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines.

Hazan-Halevy I, Landesman-Milo D, Rosenblum D, Mizrahy S, Ng BD, Peer D. Hazan-Halevy I, et al. Among authors: rosenblum d. J Control Release. 2016 Dec 28;244(Pt B):149-156. doi: 10.1016/j.jconrel.2016.07.052. Epub 2016 Aug 2. J Control Release. 2016. PMID: 27491881 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results